What Does the Falsified Medicines Directive (FMD) Mean for SMEs and CMOs; and More Importantly, Are These Organisations Ready?

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

What Does the Falsified Medicines Directive (FMD) Mean for SMEs and CMOs; and More Importantly, Are These Organisations Ready?

The implications of the directive are far-reaching and affect
all pharmaceutical manufacturers, regardless of size. As
time runs out and the deadline grows ever closer, Christian
Taylor of Zetes explains in his article how CMOs and
SME pharmaceutical manufacturers can ensure they are
compliant. If smaller organisations embrace the regulatory
changes – using them as an opportunity to optimise their
supply chains, they can create true business value, making
it pay to be compliant.